Almac Group Uses HP Software to Bring New Drugs to Market Faster

HP today announced that the Almac Group, a global pharmaceutical services provider based in Ireland, has used HP software to reduce the time required to put new drugs through clinical trials.

Every drug under development must be scrutinized in a clinical trial, which requires customized software applications that go through a complex compliance and validation process before the trial can proceed. By using HP Quality Center software to automate the testing process for these applications, Almac has reduced the validation time by months, which means that drugs for cancer and other illnesses can get to patients faster.

“By using HP technology we help speed the move from innovation to clinical practice, resulting in significant market advantage and enhanced competitiveness for our customers across the world,” said Sir Allen McClay, chairman, Almac Group. “Our 15-year relationship with HP has extended far beyond hardware and software; we are engaging with people who can bring innovative technology solutions to science and produce something mutually beneficial.”

Almac has achieved full Pharmaceutical Validation for HP Quality Center software, enabling it to automate its approach to software validation and testing. Almac’s achievements in applying the technology in the pharmaceutical sector were recently showcased at a global ICT summit on software in Vienna, Austria.

“HP is helping Almac shorten the validation aspects of its software development while at the same time ensuring that it can meet manufacturing best practices globally,” said Martin Murphy, managing director, Northern Ireland, HP. “HP Quality Center software helps IT organizations save time and deliver applications that do exactly what the businesses need.”